A look at the biologics, gene therapies, and vaccines most likely to reshape care —and manufacturing—in the year ahead.
Fourth quarter 2025 net product revenue from global sales of IMCIVREE® (setmelanotide) of $57.3 million -- -- March 20, 2026 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results